CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?
CRISPR Therapeutics Ownership Summary
CRISPR Therapeutics is owned by 76.47% institutional investors, 1.79% insiders, and 21.73% retail investors. Ark investment management is the largest institutional shareholder, holding 10.53% of CRSP shares. ARK Innovation ETF is the top mutual fund, with 7.94% of its assets in CRISPR Therapeutics shares.
CRSP Ownership Benchmark
Type | Name | % Inst | % Insiders | % Retail |
---|---|---|---|---|
Stock | CRISPR Therapeutics | 76.47% | 1.79% | 21.73% |
Sector | Healthcare Stocks | 57.00% | 9.26% | 33.74% |
Industry | Biotech Stocks | 68.69% | 8.88% | 22.43% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
Holder | Shares | % Holding | Value |
---|---|---|---|
Ark investment management | 8.97M | 10.53% | $353.18M |
Capital investors | 8.74M | 10.26% | $344.15M |
T. rowe price investment management | 3.81M | 4.47% | $150.03M |
Blackrock | 2.78M | 3.40% | $150.03M |
Blackrock funding, inc. /de | 2.76M | 3.24% | $108.61M |
Sumitomo mitsui trust | 2.75M | 3.22% | $108.07M |
Nikko asset management americas | 2.75M | 3.22% | $108.07M |
State street | 2.49M | 2.95% | $98.07M |
Fmr | 2.22M | 2.61% | $87.51M |
Ubs group | 1.98M | 2.33% | $78.09M |
Top Institutional Shareholders by % of Total Assets
Holder | Shares | % Assets | Value |
---|---|---|---|
Versant venture management | 498.56K | 22.62% | $19.62M |
Sr one capital management, lp | 1.05M | 10.07% | $41.29M |
Spear rsc | 165.00K | 6.29% | $8.91M |
Nea management company | 1.59M | 3.53% | $62.50M |
Ark investment management | 8.97M | 2.94% | $353.18M |
Contrarius investment management | 685.72K | 2.32% | $37.04M |
Ecor1 capital | 1.39M | 2.07% | $54.68M |
Eagle health investments lp | 197.00K | 1.87% | $10.64M |
Nikko asset management americas | 2.75M | 1.17% | $108.07M |
Green alpha advisors | 24.63K | 0.78% | $969.40K |
Top Buyers
Holder | Shares | % Assets | Change |
---|---|---|---|
Orbis allan gray | 1.48M | 0.31% | 1.48M |
Ark investment management | 8.97M | 2.94% | 1.47M |
Ubs group | 1.98M | 0.01% | 1.31M |
T. rowe price investment management | 3.81M | 0.09% | 1.07M |
Capital investors | 8.74M | 0.06% | 816.79K |
Top Sellers
Holder | Shares | % Assets | Change |
---|---|---|---|
Bellevue group | - | - | -610.00K |
Farallon capital management | - | - | -530.00K |
State street | 2.49M | 0.00% | -501.46K |
Morgan stanley | 597.68K | 0.00% | -488.25K |
Federated hermes | - | - | -447.61K |
New Positions
Holder | Shares | % Assets | Change | Value |
---|---|---|---|---|
Orbis allan gray | 1.48M | 0.31% | 1.48M | $58.10M |
Norges bank | 443.54K | 0.00% | 443.54K | $17.46M |
Susquehanna fundamental investments | 92.39K | 0.05% | 92.39K | $3.64M |
Imc-chicago | 86.47K | 0.00% | 86.47K | $3.40M |
Raymond james financial | 82.09K | 0.00% | 82.09K | $3.23M |
Sold Out
Holder | Change |
---|---|
Impact partnership wealth | -1.00 |
Toronto dominion bank | -4.00 |
Baldwin brothers llc/ma | -4.00 |
Financial gravity asset management | -5.00 |
Abich financial wealth management | -6.00 |
Institutional Ownership Trends
Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2024 | 420 | -5.83% | 64,513,268 | 8.48% | 76 | 1.57% | 174 | - | 118 | -10.61% |
Sep 30, 2024 | 437 | -9.15% | 59,424,788 | -0.24% | 69 | 1.31% | 167 | -19.71% | 131 | 1.55% |
Jun 30, 2024 | 478 | -7.54% | 59,547,600 | 1.78% | 72 | 1.42% | 205 | -12.02% | 129 | -9.15% |
Mar 31, 2024 | 517 | 0.58% | 58,507,242 | 5.59% | 71 | 1.48% | 233 | -10.73% | 142 | 15.45% |
Dec 31, 2023 | 514 | 17.62% | 55,408,078 | 0.82% | 69 | 1.45% | 261 | 31.16% | 123 | 14.95% |
Top Mutual Funds Shareholders
Holder | Shares | % Holding | Change |
---|---|---|---|
ARK Innovation ETF | 6.81M | 7.94% | 236.55K |
ARK Disruptive Innovation Full Composite | 6.44M | 7.54% | 1.25M |
American Funds New Perspective A | 4.79M | 5.61% | 100.58K |
Capital Group New Perspective Comp | 4.79M | 5.61% | 100.58K |
ARK Genomic Revolution ETF | 1.85M | 2.15% | 4.57K |
ARK Genomic Revolution | 1.79M | 2.10% | 33.41K |
SPDR® S&P Biotech ETF | 1.79M | 2.10% | -17.39K |
American Funds SMALLCAP World A | 1.62M | 1.90% | 489.84K |
T. Rowe Price US Mid-Cap Growth Equity | 1.50M | 1.75% | 501.10K |
T. Rowe Price Mid-Cap Growth | 1.50M | 1.75% | - |
Recent Insider Transactions
Date | Name | Role | Activity | Value |
---|---|---|---|---|
Feb 19, 2025 | Kulkarni Samarth | Chief Executive Officer | Sell | $365.80K |
Feb 19, 2025 | Bruno Julianne | Chief Operating Officer | Sell | $17.58K |
Feb 18, 2025 | Kulkarni Samarth | Chief Executive Officer | Sell | $640.78K |
Feb 19, 2025 | KASINGER JAMES R. | General Counsel and Secretary | Sell | $102.80K |
Feb 18, 2025 | KASINGER JAMES R. | General Counsel and Secretary | Sell | $516.69K |
Insider Transactions Trends
Date | Buy | Sell |
---|---|---|
2025 Q1 | - | 5 |
2024 Q4 | - | 5 |
2024 Q3 | - | - |
2024 Q2 | - | 3 |
2024 Q1 | - | 15 |
CRSP Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools